Novo Nordisk's Danish Drama: A CEO Under Fire While the Stock Sits in the Weeds
Published on 08/18/2026 at 13:07 | Redaktion boerse-global.de
The world's most valuable pharmaceutical company is learning that pipeline setbacks and personnel problems can be just as punishing as a missed earnings target. Novo Nordisk's stock is trading roughly 30 percent below its January peak of 54.86 euros, and the company's chief executive is now fighting a two-front war: one against competitors encroaching on its weight-loss turf, and another against a restive workforce facing the largest layoff in Danish corporate history.
Chief Executive Mike Doustdar took the unusual step this week of addressing workplace culture concerns directly on LinkedIn, responding to criticism from unions and a former company stress adviser. The public intervention signals just how combustible the internal situation has become, with approximately 5,000 job cuts on the table. Union leaders like Djøf chair Sara Vergo are pressing for better transition prospects for affected members, while works councils scramble to limit the scope of the reductions.
The personnel turmoil lands at a delicate moment for the Danish drugmaker. Its CagriSema combination therapy—the product many investors view as the company's best answer to Eli Lilly's Zepbound—produced weaker-than-hoped trial results earlier this month, knocking the shares down 2.6 percent in the sessions that followed. Doustdar has publicly pushed back on the notion that the obesity market will crown a single winner, arguing that oral formulations and a more diversified portfolio will keep Novo Nordisk competitive. He also reaffirmed plans to launch CagriSema next year despite the disappointing data.
The stock's technical picture offers little comfort. At a recent 38.87 euros, the shares sit below all major moving averages, with the gap to the 200-day average at 3.5 percent. The relative strength index hovers near 40—not yet oversold, but a clear reflection of persistent downward momentum. Year-to-date losses stand at 11 percent, and the past month alone has erased 10 percent of the share price.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Management's response to the slide has been to lean harder into its buyback program. The company confirmed additional repurchases on August 10 and 14 under a 15 billion Danish kroner initiative, having already bought back nearly 28.9 million B-shares for roughly 8.08 billion kroner within a sub-program capped at just over 11.2 billion kroner. The buying has done little to arrest the decline—the stock has shed 13.6 percent since the program was expanded three weeks ago.
On the legal front, Novo Nordisk secured two victories in the Netherlands this month. A court issued a preliminary injunction against Ceban Ziekenhuisfarmacie over semaglutide patent infringement, ordering the company to halt disputed activities, remove offers, disclose supply chain details, and cover procedural costs. A separate ruling blocked an unauthorized compounded semaglutide nasal spray, which the company framed as a patient-safety measure.
The pipeline picture is more mixed. A partnership with Amazon Web Services announced in early August aims to accelerate drug development through artificial intelligence. But a smaller setback emerged when Scholar Rock removed Novo Nordisk's Indiana manufacturing site from its FDA filing for a rare neuromuscular disease treatment, weakening the direct link between the two companies on that program.
Investors remain unconvinced despite the operational wins. First-half results delivered two weeks ago with an upgraded full-year outlook failed to shift the mood, nor did the company's repeated guidance raises throughout the year—moves analysts had largely anticipated. A U.S. securities lawsuit alleging misleading statements around the REDEFINE 1 CagriSema trial has also added to the overhang, with a federal judge recently allowing portions of the claims to proceed.
Danish commentators note the broader market impact: the domestic C25 index has managed just 4.1 percent gains this year, trailing European and American benchmarks largely because of Novo Nordisk's underperformance. With the workforce question now a standalone risk factor, Doustdar's credibility rests on whether he can steady internal morale while delivering the sales numbers and CagriSema launch that the market is waiting to see.
Ad
Novo Nordisk Stock: New Analysis - 18 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
